Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $570.58, for a total value of $5,420,510.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $23,115,907.54. The trade was a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

United Therapeutics Trading Down 1.6%

NASDAQ:UTHR opened at $572.20 on Wednesday. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $607.89. The stock has a market cap of $24.18 billion, a price-to-earnings ratio of 20.51, a PEG ratio of 1.65 and a beta of 0.60. The stock has a 50-day moving average price of $545.81 and a two-hundred day moving average price of $499.25.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. During the same period in the previous year, the firm earned $6.19 earnings per share. The company’s revenue was up 7.4% on a year-over-year basis. Sell-side analysts forecast that United Therapeutics Corporation will post 27.97 earnings per share for the current year.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of UTHR. Wellington Management Group LLP raised its holdings in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares in the last quarter. Darwin Global Management Ltd. bought a new stake in United Therapeutics during the third quarter worth about $317,617,000. Norges Bank bought a new stake in United Therapeutics during the fourth quarter worth about $293,418,000. Avoro Capital Advisors LLC raised its holdings in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares in the last quarter. Finally, Janus Henderson Group PLC raised its holdings in United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after acquiring an additional 341,383 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on UTHR shares. Raymond James Financial started coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Oppenheimer upped their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Royal Bank Of Canada upped their price objective on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Bank of America upped their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Finally, HC Wainwright upped their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Ten equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $601.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.